Telix Pharmaceuticals: Scope Of Company Beyond Radio Antibody-Drug Conjugate TLX591-Tx

Terry ChrisomalisInvesting Group LeaderFollow5ShareSavePlay(14min)Comment(1)SummaryTelix Pharmaceuticals (TLX) maintains a "Buy" rating, driven by robust revenue growth and multiple late-stage oncology assets.TLX reported FY2025 revenue of $804 million, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622 million.Lead asset TLX591-Tx advances in phase 3 for mCRPC, while TLX250-Tx targets ccRCC in both monotherapy and combination trials.Key risks include sustainability of revenue growth, clinical trial outcomes, and potential myelotoxicity in TLX250-Tx studies.Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Luis Alvarez/DigitalVision via Getty Images The last time I spoke about Telix Pharmaceuticals (TLX) it was with respect to a Seeking Alpha article entitled "Telix Pharma Stock: Prostate Cancer Treatments Could Lead To Increased Value." With respect to this article, I notedThis article was written byTerry Chrisomalis14.78K FollowersFollowTerry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.